Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 3, 2012, Pages 284-289

  Topkan, Erkan ^a   Topuk, Savaş ^a   Oymak, Ezgi ^a   Parlak, Cem ^b   Pehlivan, Berrin ^c  

^a BASKENT UNIVERSITY   (Turkey)

^b Antalya Education and Research Hospital ^*  (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

Author keywords

chemoradiotherapy; glioblastoma multiforme; pseudoprogression

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN BIOPSY; BRAIN RADIATION; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEALTH CARE POLICY; HISTOPATHOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84861528583     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318210f54a     Document Type: Article

References (22)

1. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuVant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuVant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10: 459-466
3. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280
4. Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82:81-83
5. Jefferies S, Burton K, Jones P, et al. Interpretation of early imaging after concurrent radiotherapy and temozolomide for glioblastoma. Clin Oncol (R Coll Radiol). 2007;19:S33
6. Taal W, Brandsma D, de Bruin HG, et al. Incidence of pseudoprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008;113:405-410
7. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26: 2192-2197
8. Roldan GB, Scott JN, McIntyre JB, et al. Population based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci. 2009;36:617-622
9. Chaskis C, Neyns B, Michotte A, et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol. 2009;72:423-428
10. Sanghera P, Perry J, Sahgal A, et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci. 2010;37:36-42
11. Yaman E, Buyukberber S, Benekli M, et al. Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. Clin Neurol Neurosurg. 2010;112:662-667
12. Kang HC, Kim CY, Han JH, et al. Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. J Neurooncol 2011;102:157-162
13. De Wit MC, de Bruin HG, Ejkenboom W, et al. Immediate postradiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63:535-537
14. Brandes AA, Rigon A, Monfardini S, et al. Radiotherapy of the brain in elderly patients. Contra. Eur J Cancer. 2000;36: 447-452
15. DeAngelis LM, Delattre JY, Posner JB, et al. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989; 39:789-796
16. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomidemediated radiation enhancement in glioblastoma. A report on underlying mechanisms. Clin Cancer Res. 2006;12:4738-4746
17. Hoffman WF, Levin VA, Wilson CB, et al. Evaluation of malignant glioma patients during the postirradiation period J Neurosurg. 1979;50:624-628
18. Stupp R, Dietrich P-Y, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuVant temozolomide. J Clin Oncol. 2002;20: 1375-1382
19. Gahramanov S, Raslan AM, Muldon LL, et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast- enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys. 2011;79:514-523
20. Tsien C, Galbin CJ, Cheenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010;28: 2293-2299
21. Pytel P, Lukas RV. Update on diagnostic practice: tumors of the nervous system. Arch Pathol Lab Med. 2009;133:1062-1077
22. Fabi A, Russillo M, Metro G, et al. Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice Anticancer Res. 2009;29:2607-2610